The efficiency of immunotherapy can be affected by genetic and molecular alterations in the primary tumour, such as the mitogen-activated protein kinase (MAPK), which upon activation leads to secretion of cytokines such as VEGF and IL-10, which decreases cytotoxic T-cell effectiveness and infiltration of the tumour. This evidence concerns the gene IL10 and neoplasm.